CIK 0000899923
- Accelerated filer
MYRIAD GENETICS INC
Sign in to watch- Ticker
- MYGN
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 870494517
- Phone
- +1 801-584-3600
- Business address
- 322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
- Former names
- MYRIAD GENETICS INC
- 4 Returned to the company President & C.E.O. returned 27,022 shares (to the company)
- 3 Insider Initial Statement of Ownership
- 4 Returned to the company President & C.E.O. returned 34,095 shares (to the company)
- 4 Returned to the company President Crescendo BioScience returned 9,297 shares (to the company)
- 4 Returned to the company President Myriad RBM, Inc. returned 5,609 shares (to the company)
- 4 Returned to the company President Assurex Health Inc. returned 5,794 shares (to the company)
- 4 Returned to the company Exec. VP International Ops returned 6,321 shares (to the company)
- 4 Returned to the company E.V.P., General Counsel returned 820 shares (to the company)
- 4 Returned to the company President, MGL returned 1,269 shares (to the company)
- 4 Returned to the company President, MWH returned 11,920 shares (to the company)
- 4 Returned to the company Chief Scientific Officer returned 9,758 shares (to the company)
- 3 Insider Initial Statement of Ownership
- 4 Returned to the company Chief Financial Officer returned 11,920 shares (to the company)
- 5 Insider Annual Insider Trading Report
- 4 Open-market sale President & C.E.O. sold 137,000 shares at $44.00 ($6,028,000)
- 4 Open-market sale Exec. VP International Ops sold 60,000 shares at an average $43.49 ($2,609,329)
- 4 Open-market sale President Crescendo BioScience sold 11,712 shares at $40.00 ($468,480)
- 4 Open-market sale Chief Financial Officer sold 25,000 shares at $41.50 ($1,037,575)
- 3 Insider Initial Statement of Ownership
- 5 Insider Annual Insider Trading Report
Page 24 of 65 · 1,294 filings